These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16622274)

  • 1. Aromatase inhibitor withdrawal response in metastatic breast cancer.
    Cigler T; Goss PE
    J Clin Oncol; 2006 Apr; 24(12):1955-6. PubMed ID: 16622274
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
    Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
    Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports.
    Jiménez-Gordo AM; de las Heras B; Zamora P; Espinosa E; González-Barón M
    Gynecol Oncol; 2000 Jan; 76(1):126-7. PubMed ID: 10620455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic Consensus on endocrinotherapy for breast cancer].
    Jiang ZF; Xu BH; Song ST
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness of LH-RH agonist for bone metastases of breast cancer--report of a case].
    Kudoh S; Kawamura H; Suzuki Y; Matsuzaki M; Nishina M; Tsukamoto M
    Gan To Kagaku Ryoho; 1996 May; 23(6):787-90. PubMed ID: 8645031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
    von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M
    Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of pain reduction upon injecting goserelin acetate using an ice pack].
    Ikeda K; Ogawa Y; Nagahara H; Xiang Z; Sakurai K; Fukuoka T; Tokunaga S; Nishiguchi Y
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):291-3. PubMed ID: 20154487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
    Parton M; Smith IE
    J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
    [No Abstract]   [Full Text] [Related]  

  • 14. Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling.
    Vandenput I; Vergote I; Amant F; Neven P; Paridaens R; Christiaens MR
    Breast J; 2006; 12(5):507-8. PubMed ID: 16958981
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer.
    Bodmer A; Castiglione-Gertsch M
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S28-37. PubMed ID: 21943985
    [No Abstract]   [Full Text] [Related]  

  • 16. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer (metastatic).
    Stebbing J; Crane J; Gaya A
    Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
    [No Abstract]   [Full Text] [Related]  

  • 19. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
    Briest S; Wolff AC
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1243-53. PubMed ID: 17892424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.